Research ArticleRESEARCH

Investigation into the Potential of Electroporation Facilitated Topical Delivery of Cyclosporin A

Hong-Zhuo Liu, Yong-Jun Wang, Lu Xu and San-Ming Li
PDA Journal of Pharmaceutical Science and Technology May 2010, 64 (3) 191-199;

References

  1. 1.↵
    1. Lallemand F.,
    2. Felt-Baeyens O.,
    3. Besseghir K.,
    4. Benar-Cohen F.,
    5. Gumy R.
    Cyclosporin A delivery to the eye: A pharmaceutical challenge. Eur. J. Pharm. Biopharm. 2003, 56 (3), 307–318.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Hultsch T.,
    2. Kapp A.,
    3. Spergel J.
    Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005, 211 (2), 174–187.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Ho V. C.
    The use of cyclosporin in psoriasis: A clinical review. Br. J. Dermatol. 2004, 150 (suppl. 67), 1–10.
    OpenUrlPubMedWeb of Science
  4. 4.↵
    1. Guzzo C.
    Recent advances in the treatment of psoriasis. Dermatol. Clin. 1997, 15 (1), 59–68.
    OpenUrlPubMed
  5. 5.↵
    1. Zachariae H.,
    2. Kragballe K.,
    3. Hansen H.
    Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br. J. Dermatol. 1997, 136 (4), 531–535.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Duncan J. I.,
    2. Payne S. N.,
    3. Winfield A. J.,
    4. Ormerod A. D.,
    5. Thomson A. W.
    Enhanced percutaneous absorption of a novel topical cyclosporin A formulation and assessment of its immunosuppressive activity. Br. J. Dermatol. 1990, 123 (5), 631–640.
    OpenUrlPubMed
  7. 7.↵
    1. Choi H. K.,
    2. Flynn G. L.,
    3. Amidon G. L.
    Percutaneous absorption and dermal delivery of cyclosporin A. J. Pharm. Sci. 1995, 84 (5), 581–583.
    OpenUrlPubMed
  8. 8.↵
    1. Verma D. D.,
    2. Verma S.,
    3. McElwee K. J.,
    4. Freyschmidt-Paul P.,
    5. Hoffman R.,
    6. Fahr A.
    Treatment of alopecia areata in the DEBR model using cyclosporin A lipid vesicles. Eur. J. Dermatol. 2004, 14 (5), 332–338.
    OpenUrlPubMed
  9. 9.↵
    1. Tran H. S.,
    2. Malli D.,
    3. Chrzanowski F. A.,
    4. Puc M. M.,
    5. Matthews M. S.,
    6. Hewitt C. W.
    Site-specific immunosuppression using a new formulation of topical cyclosporine A with polyethylene glycol-8 glyceryl caprylate/caprate. J. Surg. Res. 1999, 83 (2), 136–140.
    OpenUrlPubMed
  10. 10.↵
    1. Verma D. D.,
    2. Fahr A.
    Synergistic penetration enhancement effect of ethanol and phospholipids on the topical delivery of cyclosporin A. J. Controlled Release 2004, 97 (1), 55–66.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Boinpally R. R.,
    2. Zhou S. L.,
    3. Devraj G.,
    4. Anne P. K.,
    5. Poondru S.,
    6. Jasti B.
    R.; Iontophoresis of lecithin vesicles of cyclosporin A. Int. J. Pharm. 2004, 274 (1–2), 185–190.
    OpenUrlPubMed
  12. 12.↵
    1. Wang S.,
    2. Kara M.,
    3. Krishnan T. R.
    Transdermal delivery of cyclosporin A using electroporation. J. Controlled Release 1998, 50 (1–3), 61–70.
    OpenUrlPubMed
  13. 13.↵
    1. Prausnitz M. R.
    A practical assessment of transdermal drug delivery by skin electroporation. Adv. Drug Deliv. Rev. 1999, 35 (1), 61–76.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Vanbever R.,
    2. Préat V.
    In vivo efficacy and safety of skin electroporation. Adv. Drug Deliv. Rev. 1999, 35 (1), 77–88.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Vanbever R.,
    2. Pliquett U. F.,
    3. Préat V.,
    4. Weaver J. C.
    Comparison of the effects of short, high-voltage and long, medium-voltage pulses on skin electrical and transport properties. J. Controlled Release 1999, 60 (1), 35–47.
    OpenUrlPubMed
  16. 16.↵
    1. Mitragotri S.
    Synergistic effect of enhancers for transdermal drug delivery. Pharm. Res. 2000, 17 (11), 1354–1359.
    OpenUrlPubMed
  17. 17.↵
    1. Zewert T. E.,
    2. Pliquett U. F.,
    3. Vanbever R.,
    4. Langer R.,
    5. Weaver J. C.
    Creation of transdermal pathways for macromolecule transport by skin electroporation and a low toxicity, pathway-enlarging molecule. Bioelectrochem. Bioenerg. 1999, 49 (1), 11–20.
    OpenUrlPubMed
  18. 18.↵
    1. Vanbever R.,
    2. Prausnitz M. R.,
    3. Préat V.
    Macromolecules as novel transdermal transport enhancers for skin electroporation. Pharm. Res. 1997, 14 (5), 638–644.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Sen A.,
    2. Zhao Y. L.,
    3. Zhang L.,
    4. Hui S. W.
    Saturated anionic phospholipids enhance transdermal transport by electroporation. Biophys. J. 2002, 83 (4), 2064–2073.
    OpenUrlPubMed
  20. 20.↵
    1. Kost J.,
    2. Pliquett U.,
    3. Mitragotri S.,
    4. Yamamoto A.,
    5. Langer R.,
    6. Weaver J.
    Synergistic effect of electric field and ultrasound on transdermal transport. Pharm. Res. 1996, 13 (4), 633–638.
    OpenUrlPubMed
  21. 21.↵
    1. Vanbever R.,
    2. Morre N. D.,
    3. Préat V.
    Transdermal delivery of fentanyl by electroporation. II. Mechanisms involved in drug transport. Pharm. Res. 1996, 13 (9), 1360–1366.
    OpenUrlPubMed
  22. 22.↵
    1. Pliquett U.,
    2. Langer R.,
    3. Weaver J. C.
    Changes in the passive electrical properties of human stratum corneum due to electroporation. Biochim. Biophys. Acta. 1995, 1239 (2), 111–121.
    OpenUrlPubMed
  23. 23.↵
    1. Vanbever R.,
    2. Lecouturier N.,
    3. Préat V.
    Transdermal delivery of metoprolol by electroporation. Pharm. Res. 1994, 11 (11), 1657–1662.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Vanbever R.,
    2. Leroy M. A.,
    3. Préat V.
    Transdermal permeation of neutral molecules by skin electroporation. J. Controlled Release 1998, 54 (3), 243–250.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Lombry C.,
    2. Dujardin N.,
    3. Préat V.
    Transdermal delivery of macromolecules using skin electroporation. Pharm. Res. 2000, 17 (1), 32–37.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Prausnitz M.
    A practical assessment of transdermal drug delivery by skin electroporation. Adv. Drug Del. Rev. 1999, 35 (1), 61–76.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Pliquett U. F.,
    2. Martin G. T.,
    3. Weaver J. C.
    Kinetics of the temperature rise within human stratum corneum during electroporation and pulsed high-voltage iontophoresis. Bioelectrochemistry 2002, 57 (1), 65–72.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Vanbever R.,
    2. LeBoulengé E.,
    3. Préat V.
    Transdermal delivery of fentanyl by electroporation. I. Influence of electrical factors. Pharm. Res. 1996, 13 (4), 559–565.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Zewert T. E.,
    2. Pliquett U. F.,
    3. Langer R.,
    4. Weaver J. C.
    Transdermal transport of DNA antisense oligonucleotides by electroporation. Biochem. Biophys. Res. Commun. 1995, 212 (2), 286–292.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Pliquett U.,
    2. Weaver J. C.
    Electroporation of human skin: Simultaneous measurement of changes in the transport of two fluorescent molecules and in the passive electrical properties. Bioelectrochem. Bioenerg. 1996, 39 (1), 1–12.
    OpenUrl
  31. 31.↵
    1. Vanbever R.,
    2. Prausnitz M. R.,
    3. Préat V.
    Macromolecules as novel transdermal transport enhancers for skin electroporation. Pharm. Res. 1997, 14 (5), 638–644.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Weaver J. C.,
    2. Vanbever R.,
    3. Vaughan T. E.,
    4. Prausnitz M. R.
    Heparin alters transdermal transport associated with electroporation. Biochem. Biophys. Res. Commun. 1997, 234 (3), 637–640.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Sen A.,
    2. Zhao Y.,
    3. Zhang L.,
    4. Hui S. W.
    Enhanced transdermal transport by electroporation using anionic lipids. J. Controlled Release 2002, 82 (2–3), 399–405.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Murthy S. N.,
    2. Sen A.,
    3. Hui S. W.
    Surfactant-enhanced transdermal delivery by electroporation. J. Controlled. Release 2004, 98 (2), 307–315.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Liu H.,
    2. Li S.,
    3. Wang Y.,
    4. Yao H.,
    5. Zhang Y.
    Effect of vehicles and enhancers on the topical delivery of cyclosporin A. Int. J. Pharm. 2006, 311 (1–2), 182–186.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Guo J. X.,
    2. Ping Q. N.,
    3. Wu T,
    4. Hu X. F.
    Pharmacokinetic of behaviors transdermal delivery and oral administration of cyclosporin A preparations in mice. J. China Pharm. University 2000, 31 (5), 340–343.
    OpenUrl
  37. 37.↵
    1. Lopes L. B.,
    2. Collett J. H.,
    3. Bentley M. V. L. B.
    Topical delivery of cyclosporin A: An in vitro study using monoolein as a penetration enhancer. Eur. J. Pharm. Biopharm. 2005, 60 (1), 25–30.
    OpenUrlPubMed
  38. 38.↵
    1. Mitragotri S.,
    2. Blankschtein D.,
    3. Langer R.
    Ultrasound-mediated transdermal protein delivery. Science 1995, 269 (5225), 850–853.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Mitragotri S.,
    2. Blankschtein D.,
    3. Langer R.
    Transdermal drug delivery using low-frequency sonophoresis. Pharm. Res. 1996, 13 (3), 411–420.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Kost J.,
    2. Pliquett U.,
    3. Mitragotri S.,
    4. Yamamoto A.,
    5. Weaver J.,
    6. Langer R.
    Enhanced transdermal delivery: synergistic effect of ultrasound and electroporation. Pharm. Res. 1996, 13 (4), 633–638.
    OpenUrlPubMed
Back to top

In This Issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Investigation into the Potential of Electroporation Facilitated Topical Delivery of Cyclosporin A
Hong-Zhuo Liu, Yong-Jun Wang, Lu Xu, San-Ming Li
PDA Journal of Pharmaceutical Science and Technology May 2010, 64 (3) 191-199;
Twitter logo Facebook logo Mendeley logo

Jump to section